

# The role of reference measurement procedures in supporting EQA

*Denise O'Sullivan PhD*

Principal Scientist, Molecular & Cell Biology, NML, LGC

[denise.osullivan@lgcgroup.com](mailto:denise.osullivan@lgcgroup.com)

## National Measurement Laboratory (NML)

Measurement matters

# National Metrology Institutes



- National Metrology Institutes (NMIs) and Designated Institutes (DIs)

# Metrology

/mɪ'trɒlədʒi/

*noun*

the scientific study of measurement.



# The BIPM: An International Organization for Metrology

*“The BIPM is an intergovernmental organization established by the Metre Convention, through which Member States act together on matters related to measurement science and measurement standards”.*

- **Founded in Paris in 1875 by 17 Member States and based at the *Pavillon de Breteuil* in Parc St Cloud, Sèvres, France**
- **Now involving over 100 states and economies as Members or Associates.**



Metrological traceability for in vitro diagnostic medical devices (adapted from ISO17511:2021)



Unit (SI)

**Reference Materials**

**Reference Measurement Procedures (RMP)**

Metrological traceability

1. Certified primary reference material

2. Primary calibrator

3. Secondary (commutable) material

4. Manufacturer's calibrator

5. Test calibrator

6. Routine sample with result

1. Measurement procedure for purity assessment

2. Primary RMP

3. RMP for calibrator

4. Manufacturer's selected measurement procedure

5. Manufacturer's standing measurement procedure

6. Test method


Reference laboratory

Test manufacturer

Test laboratory

Uncertainty





**There are also some quantities that cannot be described in terms of the seven base quantities of the SI, but have the nature of a count. Examples are a number of molecules, a number of cellular or biomolecular entities (for example copies of a particular nucleic acid sequence), or degeneracy in quantum mechanics. Counting quantities are also quantities with the associated unit one.**

# Example of Viral Genome measurement



IU/ml plasma

*Reference  
Materials*

*Measurement  
Procedures*

Reference  
laboratory

1ary reference material

2ndary reference  
material

Routine sample

qPCR

qPCR

Diagnostic  
manufacturer

Clinical  
laboratory


Result

Metrological traceability

Uncertainty



# Reverse transcription real time quantitative PCR (RT-qPCR)



Both have a  $C_q$  ( $C_t$ ) of 22



# Example of Viral Genome measurement



Copies per unit volume

*Materials*

*Measurement Procedures*

Metrological traceability

Reference laboratory

1ary reference material

2ndary reference material

qPCR


Diagnostic manufacturer

qPCR

Routine sample

Clinical laboratory

Result



Uncertainty



# Example of Viral Genome measurement



Copies per unit volume

*Materials*

*Measurement Procedures*

Metrological traceability

Reference laboratory

1ary reference material

2ndary reference material

dPCR

Diagnostic manufacturer


qPCR

Routine sample

Clinical laboratory


Result

Uncertainty




# Digital PCR

Real-time PCR  
 $1 \times 20 \mu\text{L}$  reaction



Split sample  
by dilution  
→

Digital PCR  
 $20 \times 1 \mu\text{L}$  reactions



- **Absolute counting method**
  - Counts nucleic acid molecules based on sequence
  - Binary output
- **Absolute quantification**
  - It is calibration free for quantification (unlike most methods that are relative)
  - High sensitivity
  - Predictable precision
- **Value assignment for calibrators or reference materials**

# dPCR as a reference method

*Clin Chem* (2018) 64(9):1296-1307

## Assessment of Digital PCR as a Reference Measurement Procedure to Support Precision Medicine

Alexandra S. Whale,<sup>1†</sup> Gerwyn M. Jones,<sup>1†</sup> Jernej Pavšič,<sup>2,3</sup> T. Sema Akyürek,<sup>4</sup> Müslüm Akgöz,<sup>4</sup> Carla Divieto,<sup>5</sup> Maria Paola Sass Young-Kyung Bae,<sup>7</sup> Sang-Ryoul Park,<sup>7</sup> Liesbet Deprez,<sup>8</sup> Philippe Cor Raquel Larios,<sup>10</sup> Simon Cowen,<sup>11</sup> Denise M. O'Sullivan,<sup>1</sup> Claire A. Carole A. Foy,<sup>1</sup> Alison J. Woolford,<sup>1</sup> Helen Parkes,<sup>1</sup> Jim F. Huggett

*Methods* (2022) 201:65-73



Contents lists available at ScienceDirect

Methods

journal homepage: [www.elsevier.com/locate/ymeth](http://www.elsevier.com/locate/ymeth)



The performance of human cytomegalovirus digital PCR reference measurement procedure in seven external quality assessment schemes over four years

Mojca Milavec<sup>a,\*</sup>, Jernej Pavšič<sup>a</sup>, Alexandra Bogožalec Košir<sup>a</sup>, Gerwyn M. Jones<sup>b</sup>, Denise M. O'Sullivan<sup>b</sup>, Alison S. Devonshire<sup>b</sup>, Fran Van Heuverswyn<sup>d,1</sup>, Maria Karczmarczyk<sup>d,2</sup>, Jannika Neeb<sup>e,3</sup>, Annabell Plauth<sup>e</sup>, Philippe Corbisier<sup>d</sup>, Heinz Schimmel<sup>d</sup>, Andreas Kummrow<sup>e</sup>, Jörg Neukammer<sup>e,4</sup>, Carole A. Foy<sup>b</sup>, Martin Kammel<sup>f,g</sup>, Hans-Peter Grunert<sup>h</sup>, Heinz Zeichhardt<sup>f,g,h</sup>, Jim F. Huggett<sup>b,c</sup>

*Methods* (2022) 201:34-40

## An Assessment of the Reproducibility of Reverse Transcription Digital PCR Quantification of HIV-1

Samreen Falak<sup>\*1</sup>, Rainer Macdonald<sup>1</sup>, Eloise J Busby<sup>2</sup>, Denise M O'Sullivan<sup>2</sup>, Mojca Milavec<sup>3</sup>, Annabell Plauth<sup>1</sup>, Martin Kammel<sup>4,5</sup>, Heinz Zeichhardt<sup>4,5</sup>, Hans-Peter Grunert<sup>6</sup>, Andreas Kummrow<sup>\*1</sup>, Jim F. Huggett<sup>\*2,7</sup>

to improve the  
ve molecular  
tuberculosis

honeyborne<sup>2</sup>, Gerwyn Jones<sup>1</sup>, Maria Karczmarczyk<sup>3</sup>,  
Mendoza<sup>5</sup>, Heinz Schimmel<sup>3</sup>, Fran Van Heuverswyn<sup>3</sup>,  
ni<sup>6</sup>, Kathryn Harris<sup>7</sup>, Marinus Barnard<sup>8,9</sup>,  
ballis<sup>11</sup>, Keshree Pillay<sup>11</sup>, Thomas Barry<sup>12</sup>, Kate Reddington<sup>12</sup>,  
anettin Yalçinkaya<sup>14</sup>, Muslum Akgöz<sup>14</sup>, Jana Žel<sup>4</sup>,  
1,2,15\*

Results of the search

Your search criteria produced 1 result.

For more information on a reference measurement method/procedure for a given Analyte/Matrix (or Material)/Measurement principle (or technique) combination, select one or more of the options below.

Select all items from the list

Sort by :  Analyte  Measurement principle/technique  Matrix/Material

Select	Analyte	Measurement principle/technique	Matrix/Material
<input type="checkbox"/>	KRAS DNA wild type sequence and gene mutation	Digital PCR	calibration solution

Deselect all items from the list

View

Modify your search criteria

Survey Form

JCTLM Newsletters

- Issue 3 - February 2016
- Previous Issues

JCTLM

- Preamble
- Joint Committee for Traceability in Laboratory Medicine (JCTLM)
- Leaflet

Download entries as PDF

Select an analyte category

Nucleic acids

Select a matrix category

Download

Download

Results of the search

Your search criteria produced 1 result.

For more information on a reference measurement method/procedure for a given Analyte/Matrix (or Material)/Measurement principle (or technique) combination, select one or more of the options below.

Select all items from the list


Sort by :  Analyte  Measurement principle/technique  Matrix/Material

Select	Analyte	Measurement principle/technique	Matrix/Material
<input type="checkbox"/>	Human cytomegalovirus (HCMV) DNA sequence	Digital PCR	other

Deselect all items from the list

View

Modify your search criteria



- 21 Laboratories were told the sequence of the two genes to measure
- RNA in buffered solution provided/
  - i. No recommended assays
  - ii. No calibrators provided

# Example of Viral Genome measurement




Copies per unit volume

*Materials*

*Measurement Procedures*

Metrological traceability



Uncertainty



# SI traceable via counting

*Materials*

*Measurement  
Procedures*

Sources  
of bias

Reference  
laboratory

Diagnostic  
manufacturer

Clinical  
laboratory

Uncertainty

Metrological traceability

Calibration material  
*Defined (high) purity*

1ary reference material

2ndary reference  
material




Routine sample

dPCR

qPCR

qPCR

Result



# What am I counting (Virus genome)?

## Whole molecule (functional genome)

CTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGAAGCTC  
 GATGCGACATGATCATGCGGATCGCATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGC  
 TCGATGCGACATGATCATGCGGATCGATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAT  
 GATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGA  
 GCTCGATGCGACATGATCATGCGGATCGAG



## Whole molecule (defective genome)

CTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGAAGCTC  
 GATGCGACATGATCATGCGGATCGCATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGC  
 TCGATGCGACATGATCATGCGGATCGATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGC  
 GACATGATCATGCGGATCGATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATG  
 CGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAG




## Fragment

CTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGAAGCTC  
 GATGCGACATGATCATGCGGATCGCATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGCTCGATGCGACATGATCATGCGGATCGAGC  
 TCGATGCGACATGATCATGCGGATCGATG





# SARS-CoV-2 testing





# SARS-CoV-2 testing



1. Analysis only

2. Full analytical process

3. Full diagnostic process



# Digital PCR supporting characterisation of EQA materials

INSTAND-EXTERNAL QUALITY ASSESSMENT SCHEMES

MANUAL



Extra INSTAND EQAS –  
Virus Genome Detection (340)  
Coronavirus SARS-CoV-2

performed in cooperation with  
National Consultant Laboratory for Coronaviruses,  
Institute of Virology, Charité – University Medicine Berlin,  
Campus Charité Mitte, Prof. Dr. Christian Drosten,  
Dr. Victor M. Corman, Dr. Daniela Niemeyer



**IQVD**

**NIST**  
National Institute of  
Standards and Technology  
U.S. Department of Commerce



Table 3: Qualitative results –

Summary of sample properties, target values, results, success rates, medians of Ct/Cp/Cq/CN values as well as the reported minimum Ct/Cp/Cq/CN value and reported maximum Ct/Cp/Cq/CN value – differentiated according to the targeted gene region

Sample no.	Sample properties	Expected qualitative result for SARS-CoV-2	Gene region	Correct results per reported results differentiated by gene region	Reported Ct/Cp/Cq/CN-results differentiated by gene region median (min – max)
Sample 340059 <sup>5*</sup>	SARS-CoV-2 1 : 1 000 diluted  sample not evaluated <sup>5</sup>	positive	E	373/373 (100%)	22.6 (16.8-34.0)
			N	165/167 (98.8%)	23.6 (17.9-34.9)
			ORF1a	45/46 (97.8%)	22.2 (20.8-28.7)
			ORF1ab	48/48 (100%)	21.8 (10.9-29.1)
			RdRP	185/185 (100%)	23.8 (10.0-34.5)
			S	100/100 (100%)	21.8 (17.5-27.8)
			n.s. <sup>§</sup>	64/64 (100%)	22.6 ( 9.4-33.0)
			total	980/983 (99.7%) <sup>§</sup>	22.8

Different gene targets  
10<sup>2</sup>-10<sup>7</sup> fold difference

Table 5 (continued): Quantitative results

Sample No.		340059* <sup>§</sup>
Sample properties		SARS-CoV-2 positive
Dilution		1 : 1 000*
Method / gene region	Participant No.	copies/ml
qPCR / N gene	1467	23 217 000
	4973	3 811 423
	4973	78 599 453
	40839	644 900
	58803	450 276
	67794	57 428 571

Same gene target  
Differences of > 2 log



# Strategy for EQA scheme June/July 2020 dPCR assigned SARS-CoV-2 concentration of samples from sensitivity panel

**Table 1: EQA Scheme Virus Genome Detection - Coronaviruses incl. SARS-CoV-2 June/July 2020 - Summary of sample properties and target values**

Program	Group	RiliBÄK	Sample	Sample properties			
				qualitative	virus	dilution	Target value of all methods copies/ml § robust mean calculated from EQAS data (* via dPCR assigned quantitative value)
			340066* <sup>1</sup>	positive* not evaluated	SARS-CoV-2 <sup>1</sup> (inactivated)	(a) 1 : 5 000 000	2 943 <sup>§,*</sup>  (1 570 ± 360)*

Event Number

# TPP



## Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0

28 September, 2020  
Geneva, Switzerland

© World Health Organization, 2020. All rights reserved.  
The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

The mention of specific companies or certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.



*A target product profile (TPP) outlines the desired 'profile' or characteristics of a target product that is aimed at a particular disease or diseases. TPPs state intended use, target populations and other desired attributes of products, including safety and efficacy-related characteristics. Such profiles can guide product research and development (R&D)*

<https://www.who.int/observatories/global-observatory-on-health-research-and-development/analyses-and-syntheses/target-product-profile/links-to-who-tpps-and-ppcs>

Key Feature	Acceptable	Desirable
Analytical sensitivity/Limit of detection	equivalent to $10^6$ genomic copies/mL or Ct $\approx$ 25-30	equivalent to $10^4$ genomic copies/mL or Ct $\approx$ > 30

## scientific reports

RESEARCH ARTICLE  
RNA reference  
RNA loads  
towards

Laura Vierbaum<sup>1</sup>,  
Ulf Duehring<sup>2</sup>,  
Holger F. Rabenau<sup>3</sup>,  
Janine Michel<sup>4</sup>,  
Simon Cowen<sup>5</sup>,  
Andreas Kummrow<sup>6</sup>,  
Martin Kammel<sup>1,2,13</sup>

1 INSTAND e.V., Rhine-Westphalia  
3 IQVD GmbH, Institute  
Virology, Charité-  
Centre for Infectious  
University Frankfurt  
site Frankfurt, He  
Translational Me  
Infektiologiezent  
Pathogens, Berlin  
11 National Meas  
Medical Science,  
13 Materials Me  
Standards and Te  
America, 14 Phy  
Saxony, German  
Applied Sciences

✉ These authors  
\* m.kammel@iqv

OPEN

## Results of German external quality assessment schemes for SARS-CoV-2 antigen detection

Laura Vierbaum<sup>1,13</sup>, Nathalie Wojtalewicz<sup>1,13</sup>, Hans-Peter Grunert<sup>3</sup>, Anika Zimmermann<sup>2</sup>, Annemarie Scholz<sup>2</sup>, Sabine Goseberg<sup>1</sup>, Patricia Kaiser<sup>1</sup>, Ulf Duehring<sup>3</sup>, Christian Drosten<sup>4</sup>, Victor Corman<sup>4</sup>, Daniela Niemeyer<sup>4</sup>, Holger F. Rabenau<sup>5</sup>, Martin Obermeier<sup>5</sup>, Andreas Nitsche<sup>6</sup>, Janine Michel<sup>7</sup>, Andreas Puyskens<sup>7</sup>, Jim F. Huggett<sup>8,9</sup>, Denise M. O'Sullivan<sup>8</sup>, Eloise Busby<sup>8</sup>, Simon Cowen<sup>9</sup>, Peter M. Vallone<sup>10</sup>, Megan H. Cleveland<sup>10</sup>, Samreen Falak<sup>11</sup>, Andreas Kummrow<sup>11</sup>, Ingo Schellenberg<sup>1,12</sup>, Heinz Zeichhardt<sup>1,2,3</sup> & Martin Kammel<sup>1,2,13</sup>

The COVID-19 pandemic illustrated the important role of diagnostic tests, including lateral flow tests (LFTs), in identifying patients and their contacts to slow the spread of infections. INSTAND performed external quality assessments (EQA) for SARS-CoV-2 antigen detection with lyophilized and chemically inactivated cell culture supernatant of SARS-CoV-2 infected Vero cells. A pre-study demonstrated the suitability of the material. Participants reported qualitative and/or quantitative antigen results using either LFTs or automated immunoassays for five EQA samples per survey. 711 data sets were reported for LFT detection in three surveys in 2021. This evaluation focused on the analytical sensitivity of different LFTs and automated immunoassays. The inter-laboratory results showed at least 94% correct results for non-variant of concern (VOC) SARS-CoV-2 antigen detection for viral loads of  $\geq 4.75 \times 10^6$  copies/mL and SARS-CoV-2 negative samples. Up to 85% had success for a non-VOC viral load of  $\sim 1.60 \times 10^6$  copies/mL. A viral load of  $\sim 1.42 \times 10^7$  copies/mL of the Delta VOC was reported positive in >96% of results. A high specificity was found with almost 100% negative SARS-CoV-2 antigen results for HCoV 229E and HCoV NL63 positive samples. Quantitative results correlated with increasing SARS-CoV-2 viral load but showed a broad scatter. This study shows promising SARS-CoV-2 antigen test performance of the participating laboratories, but further investigations with the now predominant Omicron VOC are needed.




### OPEN ACCESS

**Citation:** Vierbaum L, Wojtalewicz N, Grunert H-P, Lindig V, Duehring U, Drosten C, et al. (2022) RNA reference materials with defined viral RNA loads of SARS-CoV-2—A useful tool towards a better PCR assay harmonization. PLoS ONE 17(1): e0262656. <https://doi.org/10.1371/journal.pone.0262656>

**Editor:** Paulo Lee Ho, Instituto Butantan, BRAZIL

**Received:** August 24, 2021



# Conclusion

- Reference measurement procedures (RMP) can complement material standards to aid quantification and identification,



EUROPEAN STANDARD **EN ISO 17511**  
NORME EUROPÉENNE  
EUROPÄISCHE NORM June 2021

---

ICS 11.100.10 Supersedes EN ISO 17511:2003

English Version

**In vitro diagnostic medical devices - Requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples (ISO 17511:2020)**

<p>Dispositifs médicaux de diagnostic in vitro - Exigences pour l'établissement d'une traçabilité métrologique des valeurs attribuées aux étalons, aux matériaux de contrôle de la justesse et aux échantillons humains (ISO 17511:2020)</p>	<p>In-vitro-Diagnostika - Anforderungen an die Ermittlung metrologischer Rückführbarkeit von Werten, die Kalibratoren, Richtigkeitskontrollmaterialien und Humanproben zugeordnet sind (ISO 17511:2020)</p>
--	---



# Acknowledgements



## NML

- Eloise Busby
- Gerwyn Jones
- Daniel Evans
- Alison Devonshire
- Alexandra Whale
- Ana Fernandez-Gonzalez
- Carole Foy
- Alison Woolford
- Simon Cowen
- Jim Huggett

## GBD/IQVD

- Heinz Zeichhardt,
- Martin Kammel
- Hans-Peter Grunert
- Ulf Dühring

## NIBSC/MHRA

- Clare Morris
- Emma Bentley
- Neil Almond

## UK-HSA

- Jade Cogdale
- Maria Zambon

## NIB

- Mojca Milavec
- Alexandra Bogozalec

## NIST

- Megan Cleveland
- Peter Vallone

## PTB

- Andreas Kummrow
- Samreen Falak



Department for  
Science, Innovation  
& Technology

Bureau  
International des  
Poids et  
Mesures



The EMPIR initiative is co-funded by the European Union's Horizon 2020 research and innovation programme and the EMPIR Participating States



Thank you



[denise.osullivan@lgcgroup.com](mailto:denise.osullivan@lgcgroup.com)

